2Seventy Bio — Investor Presentation (June 2023)
41 slides from 2Seventy Bio's investor presentation, Jun 14, 2023
Slide 1: Unleash Time: 2seventy bio company presentation
Unleash Time 2seventy bio company presentation June 2023
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements These slides and the accompanying oral presentation may contain “forward-looking statements”. These statements include, but are not limited to: statements about our plans, strategies, timelines and expectations with respect to the development, man
Slide 3: The sole mission of 2seventy is to unleash the curative potential of the T cell
The sole mission of 2seventy is to “unleash the curative potential of the T cell” Our experience in drug development and deep execution capabilities in cell therapy allow us to design & deliver multi-layered, multi-modality T cell-based solutions that have the potential to address and overcome the i
Slide 4: Purpose-built strategy to unleash the curative potential of the T cell
Purpose-built strategy to unleash the curative potential of the T cell 4 • Unleash the T cell. We focus on autologous T cell therapies: proven modality with curative potential • Advanced engineering, broad scope. We apply cell engineering across both heme and solid tumors – bespoke therapies to opti
Slide 5: 2seventy – At a Glance
ABECMA Commercial ABECMA Development BMS 50/50 US $297M 2022 / $470-570M 2023* Potential $2-3B US Peak 3rd Line K3 & FDA Submission Initiation of Front Line K9 ABECMA Capacity Expansion Predictable Delivery ABECMA profitable in 2023** Cash runway into 2026** 410 employees 2seventy – At a Glance Unle
Slide 6: 2022 – 2seventy's Foundational First Year
2022 – 2seventy’s Foundational First Year Reset & rebalanced company size, shape & burn Company/Platform Built in-house DP capability to support product engine Launched “Unleash T cell” vision, culture & core values End of year runway into 2025 – now extended to 2026** ABECMA Pipeline • $297M U.S. t
Slide 7: 2023 Goals and Long-Term Drivers
• Total US revenue $470-570M shared with BMS** • Present and publish KarMMa-3 data • U.S. Approval in 3rd line • Initiate KarMMa-9 2023 Goals and Long-Term Drivers Longer-Term Drivers ABECMA Pipeline • Drive toward $2-3B ABECMA U.S. peak sales potential* • Path to profitability and sustainability •
Slide 8: ABECMA potential to be $2-3B market opportunity in US
ABECMA® potential to be $2-3B* market opportunity in US driven by label expansion, increased capacity and double-digit market growth 8 2022 Launch and Lead • Ongoing significant demand • Increased capacity across supply chain • RWE validates efficacy & safety even in difficult-to-treat populations •
Slide 9: Strong start to 2023 for ABECMA
Strong start to 2023 for ABECMA May 2023 update • Cash flow positive in 1Q23 • On track to achieve upper end of $470-570M* revenue guidance • Second aLVV suite approved; on track for sLVV approval in 1H24 • Successful DP step-up complete; additional step- ups on track for 2023 • $200-300M of operati
Slide 10: ABECMA launch growth trajectory vs CAR T therapies
$0 $25 $50 $75 $100 $125 $150 $175 $200 $225 $250 $275 $300 $325 $350 $375 $400 W W S al es (i n m illi on s) Quarter(s) Following Approval WW Sales of CAR T Therapies, by Quarter of Launch Kymriah (Novartis) Yescarta (Gilead) Tecartus (Gilead) Breyanzi (BMS) ABECMA (BMS/2seventy) Carvykti (J&J/Lege
Slide 11: More than half of eligible patients will not have access to a CAR T in 2025
Assuming capacity growth in-line with CD-19 experience, more than half of eligible patients will not have access to a CAR T in 2025 11 2023 (5L+) 2024 (3L+) 2025 (3L+) * Illustrative US Multiple Myeloma CAR T Capacity Growth Scenario 37% CAR T capacity growth 37% CAR T capacity growth 2026-30 (label
Slide 12: Even with 100% annual growth in capacity, 50% of eligible patients lack access
Even with 100% annual growth in commercial capacity, 50% of eligible patients will not be able to receive a CAR T in 2025 12 100% CAR T capacity growth 100% CAR T capacity growth * *Each figure = ~1,000 patients = RRMM patients treated with CAR T = not eligible for CAR T= RRMM patients eligible for
Slide 13: Real-world MM treatment decisions are practical and patient-driven
Real-world MM treatment decisions are practical and patient-driven 13 Efficacy Potential for deep and durable response Safety Predictable and manageable side-effect profile Real World Experience Physician real-world experience with the product Availability Slot availability in the relevant time fram
Slide 14: ABECMA real world experience reinforces paradigm-changing efficacy
ABECMA real world experience reinforces paradigm-changing efficacy 14 • ASCO 2022 physician poster on real world experience at 11 sites: safety and efficacy in the real world is consistent with KarMMa study • 77% of patients in real world study would not have met the eligibility criteria for KarMMa
Slide 15: KarMMa-3 Summary
KarMMa-3 Summary 15 These results support the use of ide-cel in patients with earlier-line relapse and triple-class–exposed RRMM, a patient population with poor survival outcomes 1. Munshi NC, et al. N Engl J Med 2021;384:705–716; 2. Raje N, et al. N Engl J Med 2019;380:1726–1737. KarMMa-3 is the fi
Slide 16: Addressable U.S. Patients on ABECMA label over time
Addressable U.S. Patients on ABECMA label over time Mu lti pl e M ye lo m a KarMMa-3 results and planned KarMMa-9 front-line study have the potential to drive label expansion into broad U.S. market opportunity Total Addressable U.S. Patient Population: ~21,000 0 5,000 10,000 15,000 20,000 25,000 202
Slide 17: KarMMa-2 and KarMMa-3 data support front-line potential
• RRMM after 2-4 prior lines of therapy and refractory to the last regimens); clinically meaningful and statistically significant improvement in PFS compared with standard regimens • Median PFS of 13.3 months vs. 4.4 months (HR:0.49) • FDA accepted sBLA submission; PDUFA date of December 16, 2023 Ka
Slide 18: Ide-cel significantly longer PFS than standard regimens
Treatment with ide-cel resulted in a significantly longer PFS than standard regimens, with a 51% lower risk of disease progression or death (Hazard Ratio: 0.49) Standard regimens 100 80 60 40 20 0 0 Pr og re ss io n- fre e s ur viv al, % Months since randomization 254 132 3 6 9 12 15 18 21 24 27 30
Slide 19: Expanding ABECMA manufacturing footprint
Expanding ABECMA manufacturing footprint Thermo Fisher Current commercial adherent LVV capacity Approximately 70 treatment centers in the U.S. as of 2022 Summit, NJ Drug product facility supporting global commercial launch. Successfully increasing monthly capacity. Resilience sLVV, significant incre
Slide 20: Pipeline
INDICATION [DRUG] TARGET TECHNOLOGY DISCOVERY STAGE R&D IND-ENABLING PRECLINICAL STUDIES CLINICAL STUDIES APPROVED PRODUCTS Multiple Myeloma [ABECMA] BCMA CAR T cell Multiple Myeloma [ABECMA] BCMA CAR T cell AML-Pediatric [SC-DARIC33] CD33 Drug-Regulated; CAR T cell (DARIC) B-NHL [bbT369] Dual B cel
Slide 21: Long-term partnership track record
Long-term partnership track record New collaborations are a key focus over next three years 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 Initial collaboration with Celgene (BMS) to advance gene therapies in oncology; $75M upfront – 1Q 2013 Updated / narrowed focus on anti-BCMA; $25M – 2Q 2
Slide 22: REGN Collaboration 2.0
REGN Collaboration 2.0: The Combinatorial Potential of Engineered T cells Leverages 2seventy’s CAR/TCR Platform with Regeneron mAbs and Bi-specifics for Solid Tumors • Builds on several previously identified product candidates advancing toward the clinic including MUC16 • Combines engineered T cells
Slide 23: 2seventy's end-to-end capabilities designed to unleash the cure
2seventy’s end-to-end capabilities designed to unleash the cure Research Platform with transformative toolkit Manufacturing Horsepower (270-MPH) to increase speed, control costs, and improve learning/iteration Translational Engine to run multiple parallel studies, integrating knowledge across all as
Slide 24: T cell research platform built to rapidly design, test, learn & iterate
T cell research platform built to rapidly design, test, learn, & iterate 1 2 3 4 5 VECTOROLOGY Maximize payload, innovative design, optimize component co-expression 4 DESIGN LVV mRNA MODALITY Take T cells to the next level, explore in vivo delivery 5 αβ T CELLS in vivo LVV MANUFACTURING Commoditize
Slide 25: New in-house manufacturing facility (270-MPH)
2seventy bio’s NEW in-house manufacturing facility (270-MPH) The heart of our translational cell therapy engine - Enable Fully Integrated Translational Cell Therapy Platform Enables manufacture and release of drug product for multiple Phase I clinical trials Co-located @ 60 Binney with research, PD
Slide 26: Majority of B-NHL patients ultimately fail CAR T therapy
Despite transforming the treatment paradigm of B-NHL, the majority of patients ultimately fail CAR T therapy We identified four key challenges in current CAR T therapies 26 CD19 Loss Target-Antigen Downregulation Loss of Tumor cell co- stimulatory ligands Challenges in B-NHL CAR T ~30% of CD19 CAR T
Slide 27: bbT369: Novel CAR T candidate for B-NHL
bbT369: Novel CAR T candidate purpose-built to address needs in B-NHL • Designed to address outstanding need in B-NHL – we believe bbT369 has the potential to increase response rate and durability of response for a larger fraction of patients. • Novel combination of antigens to address antigen escap
Slide 28: bbT369: Complete and durable tumor control in lymphoma mouse models
bbT369: Complete and durable tumor control in lymphoma mouse models bbT369 -20 20 40 60 80 100 120 0 1000 2000 3000 4000 0 500 1000 1500 2000 2500 Days Tu m or V ol. (m m 3 ) Avg T Cells /µL CAR T Cell expansion Tumor -20 20 40 60 80 100 120 0 1000 2000 3000 4000 0 500 1000 1500 2000 2500 Days Tu m
Slide 29: CRC-403 study in B-NHL open and enrolling
CRC-403 study in B-NHL open and enrolling 29 day -5 -2 day 0 day 0-30 day 30 CRC-403: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B-Cell Non-Hodgkin Lymphoma (B-NHL) Key Questions / Features QUESTIONS • Is the safety and tolerability of bbT369 in line with prior CAR Ts? • Does bbT369 s
Slide 30: PLAT-08 Trial of SC-DARIC33 in AML on Pause
PLAT-08 Trial of SC-DARIC33 in AML on Pause 30 PLAT-08 is the dose escalation Phase 1 study of SC-DARIC33 in relapsed/refractory pediatric AML, led by SCRI, and couples 2seventy bio’s drug-regulated DARIC T cell platform with SCRI’s expertise in oncology cell therapies. • As a result of a recent Gra
Slide 31: Engineered cell therapies have the potential to overcome key challenges in AML
Engineered cell therapies have the potential to overcome key challenges in AML 31 Description of issue AML targets are expressed on healthy myeloid lineage & progenitor cells; Aplasia related toxicities are likely to emerge if targeted robustly & constitutively AML originates from myeloid progenitor
Slide 32: SC-DARIC33: CD33 targeted CAR T cell with drug-regulated ON/OFF states
SC-DARIC33: CD33 targeted CAR T cell with drug-regulated ON/OFF states DARIC: a switchable CAR architecture that potentially addresses fundamental AML challenges… • Architecture enables T cell activity to be turned ON and OFF • ON state occurs at non-immunosuppressive rapamycin dose levels • OFF st
Slide 33: SC-DARIC33 in AML: drug-regulated tumor control in preclinical studies
SC-DARIC33 in AML: Sensitive, drug-regulated tumor control achieved in preclinical studies SC-DARIC33 TARGET(S) CD33-C2 TECH VHH binder Drug-regulated DARIC architecture TARGET INDICATION R/R AML pediatrics / young adults STATUS Ph1 Trial Enrolling PARTNER • Aggressively targeting AML requires pharm
Slide 34: Our Next-Gen CAR T for AML
27T32 27T32 Our Next-Gen CAR T for AML: Bold and packed with innovations Solving reduced antigen expression Novel architecture enhances sensitivity to low target density Regulatable system reduces T cell exhaustion and promotes memory Solving T cell exhaustion Regulatable system reduces risks from l
Slide 35: Differentiated toolbox to attack solid tumors
2seventy’s differentiated toolbox aims to attack solid tumors by addressing key barriers to success 35 We seek to achieve sensitive & multiplex targeting across the full range of target classes Tumor/Target Heterogeneity CAR TECH TCR TECH NEXT GEN We seek to disrupt the biological barriers to T cell
Slide 36: MUC16 CAR T displays robust activity in tumor rechallenge mouse model
MUC16 CAR T displays robust activity in tumor rechallenge mouse model MUC16 / Ovarian cancer program: designed to exploit the power of CAR T + pharmaceutical combination strategies to unlock deep responses Ovarian Cancer MUC16 CAR T Combo TARGET(S) MUC16 TECH CAR targeting prevalent MUC16 membrane-r
Slide 37: Exploring the potential of combinations to unlock solid tumors
Exploring the potential of combinations to unlock solid tumors Deepened Regeneron collaboration enables potential for clinical testing of MUC16 CAR T + mAbs and/or bi-specifics Anti-CD28 Tumor targeted co-stimulation Robust toolbox with the potential to unlock deep responses in Ovarian Cancer PD-1 i
Slide 38: MAGE-A4 Expressing Solid Tumor Program
MAGE-A4 Expressing Solid Tumor Program: A powerful MAGE-A4 TCR potency enhanced with a “flip” receptor to neutralize TGFβ Solid Tumor MAGE-A4 TCR-T Cell Therapy TARGET(S) MAGE-A4 (HLA-A*02) TECH • MAGE-A4 directed TCR • CTBR12 TGFβ flip receptor TARGET INDICATION Solid tumors STATUS Preclinical PART
Slide 39: MegaTAL Gene Editing for Hemophilia A / FVIII
MegaTAL Gene Editing for Hemophilia A / FVIII TARGET(S) Endogenous gene promoter trap knock-in of F8 transgene TECH • TSVT megaTAL gene edit • TSVT in vivo grade mRNA production / purification platform • AAV for transgene delivery • Genevant LNPs for hepatocyte delivery TARGET INDICATION Hemophilia
Slide 40: Leadership
Leadership 2seventy team 40 Board of Directors Philip Gregory, D. Phil. Chief Scientific Officer Nick Leschly Chief Kairos Officer* Dan Lynch Board Chair Jenn Snyder SVP, Corporate Communications + ~410 awesome timekeepers Marcela Maus, M.D., Ph.D. Massachusetts General Hospital (MGH) Cancer Center
Slide 41: thank you
thank you